Gainers

• Quince Therapeutics (NASDAQ:QNCX) stock moved upwards by 62.2% to $0.86 during Wednesday's pre-market session. The market value of their outstanding shares is at $29.3 million.
• Neuronetics (NASDAQ:STIM) shares moved upwards by 25.34% to $1.83. The market value of their outstanding shares is at $96.5 million.
• Talphera (NASDAQ:TLPH) stock moved upwards by 19.6% to $1.0. The market value of their outstanding shares is at $38.9 million.
• Hinge Health (NYSE:HNGE) shares moved upwards by 11.92% to $36.99. The company's market cap stands at $2.5 billion. As per the news, the Q4 earnings report came out yesterday.
• TuHURA Biosciences (NASDAQ:HURA) shares increased by 9.99% to $1.43. The market value of their outstanding shares is at $73.4 million.
• iTonic Holdings (NASDAQ:ITOC) stock moved upwards by 8.74% to $0.47. The company's market cap stands at $7.3 million.

Losers

• Upstream Bio (NASDAQ:UPB) stock fell 28.1% to $19.99 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.5 billion.
• Abpro Hldgs (NASDAQ:ABP) stock declined by 16.77% to $1.39. The market value of their outstanding shares is at $4.5 million.
• Avantor (NYSE:AVTR) stock declined by 11.92% to $9.83. The company's market cap stands at $7.6 billion. As per the press release, Q4 earnings came out today.
• Moderna (NASDAQ:MRNA) stock fell 10.07% to $37.77. The market value of their outstanding shares is at $16.4 billion.
• Allarity Therapeutics (NASDAQ:ALLR) shares fell 7.87% to $0.86. The company's market cap stands at $14.9 million.
• BNB Plus (NASDAQ:BNBX) shares decreased by 7.74% to $0.82. The market value of their outstanding shares is at $3.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.